Your browser doesn't support javascript.
loading
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.
Lee, Nathan V; Lira, Maruja E; Pavlicek, Adam; Ye, Jingjing; Buckman, Dana; Bagrodia, Shubha; Srinivasa, Sreesha P; Zhao, Yongjun; Aparicio, Samuel; Rejto, Paul A; Christensen, James G; Ching, Keith A.
Affiliation
  • Lee NV; Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America.
PLoS One ; 7(6): e39653, 2012.
Article in En | MEDLINE | ID: mdl-22745804
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazines / Triazoles / Recombinant Fusion Proteins / Nuclear Proteins / Proto-Oncogene Proteins c-met / Mitogen-Activated Protein Kinases / Proto-Oncogene Proteins B-raf Type of study: Prognostic_studies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2012 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazines / Triazoles / Recombinant Fusion Proteins / Nuclear Proteins / Proto-Oncogene Proteins c-met / Mitogen-Activated Protein Kinases / Proto-Oncogene Proteins B-raf Type of study: Prognostic_studies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2012 Document type: Article Affiliation country: United States Country of publication: United States